Basit öğe kaydını göster

dc.contributor.authorDORAN, FİGEN
dc.contributor.authorÜSKÜDAR, OĞUZ
dc.contributor.authorTOKMAK, SALİH
dc.contributor.authorArslan, Burcu
dc.contributor.authorBALLI, HÜSEYİN TUĞSAN
dc.contributor.authorUlku, Abdulalh
dc.contributor.authorAkcam, Tolga Atilgan
dc.contributor.authorBahceci, Halil Ibrahim
dc.contributor.authorPolat, Kamil Yalcin
dc.contributor.authorÖRMECİ, NECATİ
dc.contributor.authorŞİMŞEK, HALİS
dc.contributor.authorDemir, Ali
dc.contributor.authorALTINTAŞ, ENGİN
dc.contributor.authorDEMİR, MEHMET
dc.contributor.authorYALÇIN, KENDAL
dc.contributor.authorEkinci, Nazim
dc.contributor.authorOzakyol, Aysegul Harmanci
dc.contributor.authorYucesoy, Mehmet
dc.contributor.authorUygun, Ahmet
dc.contributor.authorGuerra, Vito
dc.contributor.authorDelik, Anil
dc.contributor.authorKilic, Murat
dc.contributor.authorSonsuz, Abdullah
dc.contributor.authorTokat, Yaman
dc.contributor.authorYILMAZ, SEZAİ
dc.contributor.authorBektas, Ahmet
dc.contributor.authorAKKIZ, HİKMET
dc.contributor.authorCarr, Brian I.
dc.contributor.authorKURAN, SEDEF
dc.contributor.authorKARAOĞULLARINDAN, ÜMİT
dc.date.accessioned2021-03-03T14:16:33Z
dc.date.available2021-03-03T14:16:33Z
dc.identifier.citationAKKIZ H., Carr B. I. , KURAN S., KARAOĞULLARINDAN Ü., ÜSKÜDAR O., TOKMAK S., Arslan B., DORAN F., BALLI H. T. , Ulku A., et al., "Macroscopic Portal Vein Thrombosis in HCC Patients", CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018
dc.identifier.issn2291-2789
dc.identifier.otherav_38add93c-ec8a-42e1-8c4b-45a39a3484f9
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/42188
dc.identifier.urihttps://doi.org/10.1155/2018/3120185
dc.description.abstractMacroscopic portal vein invasion (PVT) by hepatocellular carcinoma (HCC) in the liver is one of the most important negative prognostic factors for HCC patients. The characteristics of a large cohort of such patients were examined. We found that the percent of patients with PVT significantly increased with increasing maximum tumor diameter (MTD), from 13.7% with tumors of MTD 10cm. There were similar numbers of HCC patients with very large tumors with and without PVT. Thus, MTD alone was insufficient to explain the presence of PVT, as were high AFP levels, since less than 50% of high AFP patients had PVT. However, the percent of patients with PVT was also found to significantly increase with increasing blood alpha-fetoprotein (AFP) levels and tumormultifocality. A logistic regressionmodel that included these 3 factors together showed an odds ratio of 17.9 for the combination of MTD >5.0cm plus tumor multifocality plus elevated AFP, compared to low levels of these 3 parameters. The presence or absence of macroscopic PVT may therefore represent different HCC aggressiveness phenotypes, as judged by a significant increase in tumor multifocality and AFP levels in the PVT positive patients. Factors in addition to MTD and AFP must also contribute to PVT development.
dc.language.isoeng
dc.subjectKlinik Tıp
dc.subjectGASTROENTEROLOJİ VE HEPATOLOJİ
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectGastroenteroloji-(Hepatoloji)
dc.titleMacroscopic Portal Vein Thrombosis in HCC Patients
dc.typeMakale
dc.relation.journalCANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
dc.contributor.departmentÇukurova Üniversitesi , Tıp Fakültesi , İç Hastalıkları
dc.contributor.firstauthorID250900


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster